NYSE:MED Medifast (MED) Stock Price, News & Analysis $12.37 +0.11 (+0.90%) Closing price 10/30/2026 03:59 PM EasternExtended Trading$12.22 -0.15 (-1.17%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Medifast Stock (NYSE:MED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medifast alerts:Sign Up Key Stats Today's Range$12.00▼$12.4850-Day Range$11.44▼$12.6652-Week Range$9.22▼$13.45Volume231,902 shsAverage Volume124,858 shsMarket Capitalization$138.30 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Medifast, Inc. (NYSE: MED) is a health and wellness company that provides weight-management products, programs and support services. Its primary brand, OPTAVIA, offers meal-replacement products, including shakes, bars, soups and other portion-controlled foods, along with structured plans intended to help customers establish healthier eating and lifestyle habits. The company distributes its products primarily through an independent network of coaches who provide guidance, accountability and support to clients. Medifast’s offerings are marketed mainly to consumers in the United States, with an emphasis on combining nutrition products with coaching and behavior-change programs. Founded in 1980, Medifast has historically operated through a direct-to-consumer and direct-selling model. The company introduced the OPTAVIA brand in 2017, expanding its focus from individual weight-loss products to integrated programs that pair food products with coaching and ongoing client support.AI Generated. May Contain Errors. Read More Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreMED MarketRank™: 1.59384374592 of 5 starsMedifast scored higher than 32% of companies evaluated by MarketBeat, and ranked 138th out of 168 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingHold Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Medifast is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMedifast has only been the subject of 2 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Medifast are expected to grow in the coming year, from ($0.57) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.75% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 11.36, which indicates bearish sentiment.Change versus previous monthShort interest in Medifast has recently increased by 9.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.30 News SentimentMedifast has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Medifast this week, compared to 3 articles on an average week.Search Interest2 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Medifast to their MarketBeat watchlist in the last 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,265,294.00 in company stock, which represents 0.9149% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have bought 559.12% more of their company's stock than they have sold. Specifically, they have bought $1,491,594.00 in company stock and sold $226,300.00 in company stock.Percentage Held by Insiders3.70% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MED Stock News HeadlinesMedifast (NYSE:MED) Director Parsa Kiai Buys 5,557 Shares of Company StockOctober 31 at 5:37 AM | insidertrades.comMED Q3 deep dive: new Trilogy brand and coach productivity drive evolving metabolic health strategyOctober 29 at 4:38 AM | uk.finance.yahoo.comCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 1 at 1:00 AM | Digest Publishing (Ad)Medifast Q3 Loss Widens, Sees Profit In Q4, Loss In FY26; Shares UpOctober 28, 2026 | rttnews.comMedifast Is Running The Same Playbook, And I Have The Same ConcernsOctober 28, 2026 | seekingalpha.comMedifast (MED) Q3 Results Deepen Losses As Coach Decline PersistsOctober 27, 2026 | finance.yahoo.comMedifast Earnings Call: Trilogy Pivot Amid GLP-1 PressuresOctober 26, 2026 | tipranks.comInsider Selling: Medifast (NYSE:MED) Director Sells $111,951.12 in StockOctober 1, 2026 | insidertrades.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $10.66 at the beginning of 2026. Since then, MED shares have increased by 16.0% and is now trading at $12.37. How were Medifast's earnings last quarter? Medifast Inc (NYSE:MED) announced its quarterly earnings results on Monday, October, 26th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.16. The specialty retailer earned $72.05 million during the quarter, compared to analysts' expectations of $71.30 million. Medifast had a negative net margin of 13.64% and a negative trailing twelve-month return on equity of 6.90%. Read the conference call transcript. Who are Medifast's major shareholders? Medifast's top institutional shareholders include SummerHaven Investment Management LLC (0.37%). Insiders that own company stock include Parsa Kiai, Daniel R Chard, Scott Schlackman, Andrea B Thomas and Jeffrey J Brown. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Intel (INTC) and PayPal (PYPL). Company Calendar Last Earnings10/26/2026Today11/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MED's financial health is in the Green zone, according to TradeSmith. MED has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNYSE:MED CIK910329 Webwww.medifastinc.com Phone(410) 581-8042Fax410-581-8070Employees380Year Founded1981Price Target and Rating Average Price Target for Medifast$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside-3.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($3.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.67 million Net Margins-13.64% Pretax Margin-9.73% Return on Equity-6.90% Return on Assets-5.34% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.35 Sales & Book Value Annual Sales$385.79 million Price / Sales0.36 Cash Flow$0.42 per share Price / Cash Flow29.27 Book Value$16.12 per share Price / Book0.77Miscellaneous Outstanding Shares11,180,000Free Float10,769,000Market Cap$138.30 million OptionableOptionable Beta0.68 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NYSE:MED) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.